Rectal tuberculosis after infliximab therapy despite negative screening for latent tuberculosis in a patient with ulcerative colitis
Intestinal Research
;
: 183-186, 2016.
Artículo
en Inglés
| WPRIM
| ID: wpr-168223
ABSTRACT
Tumor necrosis factor-α inhibitors are now considered as standard therapy for patients with severe inflammatory bowel disease who do not respond to corticosteroids, but they carry a definite risk of reactivation of tuberculosis. We present a case in which a patient with inflammatory bowel disease developed a de novo tuberculosis infection after the start of anti-tumor necrosis factor-α treatment despite showing negative results in tuberculosis screening. Although there are many case reports of pleural, lymph nodal and disseminated tuberculosis following infliximab therapy, we present the first case report of rectal tuberculosis following infliximab therapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Tuberculosis
/
Úlcera
/
Enfermedades Inflamatorias del Intestino
/
Colitis Ulcerosa
/
Tamizaje Masivo
/
Factor de Necrosis Tumoral alfa
/
Corticoesteroides
/
Tuberculosis Latente
/
Infliximab
/
Necrosis
Tipo de estudio:
Estudio diagnóstico
/
Estudio pronóstico
/
Estudio de tamizaje
Límite:
Humanos
Idioma:
Inglés
Revista:
Intestinal Research
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS